Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mechnicov probiotics
- Development stage
- Unknown
- Lead developer
- Kye Bong-Hyeon
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Mechnikov probiotics is a microbial formulation investigated for the management of anterior resection syndrome (ARS) in patients undergoing surgery for sigmoid colon cancer. The intervention was evaluated in the POSTCARE study (NCT03531606), a randomized, double-blind, placebo-controlled trial led by Dr. Kye Bong-Hyeon at The Catholic University of Korea. The treatment regimen involves oral administration of the probiotic twice daily for four weeks, beginning one week prior to surgery and continuing for three weeks postoperatively. The therapy is designed to stabilize the intestinal microbiota and improve postoperative defecatory function, although clinical results indicated limited significant improvement in overall bowel function compared to placebo.
- Brand names
- Mechnicov probiotics
- Other names
- Mechnikov probioticsMetchnik probiotics
Beyond the preview
Go deeper on Mechnicov probiotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mechnicov probiotics.